METTL3

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Monday, October 18, 2021 - 6:00am

Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.

Key Points: 
  • Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
  • Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said Oncology is a key focus area for Ipsen as we grow our pipeline.
  • We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology.
  • Accent Therapeutics novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.